<unk>  immunization generally causes some pain and scarring at the site of injection. The main adverse effects are keloids—large, raised scars. The insertion to the deltoid muscle is most frequently used because the local complication rate is smallest when that site is used. Nonetheless, the buttock is an alternative site of administration because it provides better cosmetic outcomes.<unk>  should be given intradermally. If given subcutaneously, it may induce local infection and spread to the regional lymph nodes, causing either suppurative (production of pus) and nonsuppurative lymphadenitis. Conservative management is usually adequate for nonsuppurative lymphadenitis. If suppuration occurs, it may need needle aspiration. For nonresolving suppuration, surgical excision may be required. Evidence for the treatment of these complications is scarce. Uncommonly, breast and gluteal abscesses can occur due to haematogenous (carried by the blood) and lymphangiomatous spread. Regional bone infection <unk>  osteomyelitis or osteitis) and disseminated<unk>  infection are rare complications of<unk> tion, but potentially life-threatening. Systemic antituberculous therapy may be helpful in severe complications. When<unk>  is used for bladder cancer, around 2.9% of treated patients discontinue immunotherapy due to a genitourinary or systemic<unk> -related infection, however while symptomatic bladder<unk>  infection is frequent, the involvement of other organs is very uncommon. When systemic involvement occurs, liver and lungs are the first organs to be affected (1 week median after the last<unk>  instillation). If<unk>  is accidentally given to an immunocompromised patient (e.g., an infant with severe combined immune deficiency, it can cause disseminated or life-threatening infection. The documented incidence of this happening is less than one per million immunizations given. In 2007, the WHO stopped recommending<unk>  for infants with HIV, even if the risk of exposure to tuberculosis is high, because of the risk of disseminated<unk>  infection (which is roughly 400 per 100,000 in that higher risk context).
BCG vaccine
MMR vaccine
MMRV vaccine
Polio vaccine
Mumps vaccine
Typhus vaccine
DTaP-IPV vaccine
Measles vaccine